AUSTIN, Texas, Feb. 22, 2016 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) today announced that it has received medical device
licenses from Health Canada's Therapeutic Products Directorate,
Medical Devices Bureau for the ARIES® System and
ARIES® HSV 1&2 Assay. The ARIES® System
and HSV 1&2 Assay previously received FDA clearance in
October 2015 and were subsequently
launched in the U.S. market.
"We are excited to receive medical device licenses for the
ARIES® System and the ARIES® HSV 1&2
Assay in Canada. We look forward
to rapidly launching this revolutionary system there," said
Todd Bennett, VP, Global Sales and
Customer Operations, Luminex Corporation. "We are confident that
the ARIES® System will answer many of our Canadian
clinical laboratory customers' needs by increasing efficiency,
reducing errors, and delivering accurate and timely data to improve
patient care."
About the ARIES® System
The
ARIES® System is a sample to answer system designed to
increase laboratory efficiency, ensure result accuracy, and fit
seamlessly into today's lean laboratory environment. The
ARIES® System uses internal barcode scanning and other
advanced features to minimize operator errors. The system contains
two independent modules that support from one to six cassettes
each, allowing for both STAT and Batch testing. IVD and
MultiCode® Analyte Specific Reagents can be run
simultaneously with a common Universal Assay Protocol. An
integrated touchscreen PC eliminates the need for a separate
computer, stand-alone keyboard, and mouse, thus maximizing valuable
bench space. The ARIES® System is the most powerful and
intuitive of any sample to answer solution and provides control of
the testing process, from accession of the sample to results
reporting.
About Herpes Simplex Virus 1 and 2 (HSV-1 and 2)
HSV-1
is a contagious infection, which is common and endemic throughout
the world. The virus causes lifelong infection, and there is no
cure, although treatment can reduce symptoms. It is mainly
transmitted through oral-oral contact and causes "cold sores."
HSV-2 infection is widespread and mainly sexually transmitted. It
is estimated that up to 20 million people are newly infected with
HSV-2 each year. HSV-2 causes genital herpes, characterized by the
occasional appearance of painful genital ulcers. Prescription
antivirals to treat herpes simplex include acyclovir, famciclovir,
and valacyclovir. Serious complications occur most often in unborn
babies, newborns, and people who have a long-term illness such as
cancer or HIV/AIDS, or have a weakened immune system.
To learn more or request a demo, visit:
http://www.luminexcorp.com/ARIES
About Luminex Corporation
Luminex is committed to
applying its passion for innovation toward creating breakthrough
solutions to improve health and advance science. The company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase
chain reaction (PCR), and multiplex PCR-based technologies, that
deliver cost-effective rapid results to clinicians and researchers.
Luminex's technology is commercially available worldwide and in use
in leading clinical laboratories, as well as major pharmaceutical,
diagnostic, biotechnology, and life science companies. Luminex is
meeting the needs of customers in markets as diverse as clinical
diagnostics, pharmaceutical drug discovery, biomedical research
including genomic and proteomic research, personalized medicine,
biodefense research, and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using
award winning technology, please visit
http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward- looking statements in this release include statements
regarding the available market for ARIES® and related
assays, future revenue growth anticipated for ARIES® and
related assays, and the development, testing and regulatory
approval progress of our pipeline products, including
ARIES® related assays. The words "believe", "expect",
"intend", "anticipates", "confident", "will", "could",
"should", and similar expressions are intended to further
identify such forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results or performance could
differ materially from those anticipated in such forward-looking
statements. Factors that could cause Luminex's actual results or
performance to differ materially include risks and uncertainties
relating to, among others, our ability to launch products on time,
the timing of regulatory approvals, the outcome of clinical trials
as well as the risks discussed under the heading "Risk Factors" in
Luminex's Reports on Forms 10-K and 10-Q, as filed with the
Securities and Exchange Commission. The forward looking statements
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts:
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
Photo - http://photos.prnewswire.com/prnh/20160222/335800
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-receives-medical-device-license-for-aries-system-and-aries-hsv-12-assay-in-canada-300223861.html
SOURCE Luminex Corporation